Q3 EPS Forecast for Mirum Pharmaceuticals Raised by Analyst

Key Points

• HC Wainwright raised Mirum Pharmaceuticals’ Q3 2026 EPS forecast to $0.07 from negative $0.31 and maintained a Buy rating with a $195 price target.
• Mirum’s latest quarter missed EPS expectations, reporting a $1.06 loss per share versus the $0.74 consensus, although revenue of $176.24 million exceeded estimates and grew 37.9% year over year.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and average price target of $142.56, despite recent insider selling and the stock trading below its 50- and 200-day moving averages.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - HC Wainwright increased their Q3 2026 earnings estimates for shares of Mirum Pharmaceuticals in a report released on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.07 per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a "Buy" rating and a $195.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q4 2026 earnings at ($0.11) EPS, Q3 2027 earnings at $0.35 EPS, FY2028 earnings at $5.38 EPS, FY2029 earnings at $7.21 EPS and FY2030 earnings at $10.03 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) EPS.

A number of other equities research analysts have also recently issued reports on MIRM. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an "outperform" rating in a research report on Tuesday. Morgan Stanley set a $144.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday. Citigroup reissued a "buy" rating and issued a $160.00 price objective (up from $145.00) on shares of Mirum Pharmaceuticals in a report on Monday. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, September 6th. Finally, Weiss Ratings raised shares of Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $142.56.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $87.54 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm has a market cap of $5.68 billion, a price-to-earnings ratio of -6.02 and a beta of 0.49. The stock's fifty day moving average price is $99.74 and its two-hundred day moving average price is $101.45. Mirum Pharmaceuticals has a one year low of $63.23 and a one year high of $130.00.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer owned 36,355 shares of the company's stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer owned 194,440 shares in the company, valued at approximately $19,187,339.20. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 123,499 shares of company stock worth $12,854,484. Corporate insiders own 8.32% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC bought a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $691,672,000. Janus Henderson Group PLC lifted its stake in Mirum Pharmaceuticals by 14.5% in the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company's stock valued at $641,764,000 after purchasing an additional 880,505 shares during the last quarter. BlackRock Inc. acquired a new stake in Mirum Pharmaceuticals in the second quarter valued at approximately $513,945,000. ABS Investment Management LLC bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $245,847,000. Finally, William Blair Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the second quarter worth $164,453,000.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Atebrioz for fibrodysplasia ossificans progressiva, an ultra-rare disorder involving abnormal bone formation. Approval expands Mirum’s commercial portfolio and follows PROGRESS study data showing reduced new heterotopic ossification lesion volume. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: Mirum’s experimental hepatitis delta virus treatment brelovitug met the primary endpoint in the Phase III AZURE-1 study. The drug produced strong virologic response and alanine aminotransferase normalization results, supporting a potential future expansion into a serious liver-infection market. Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: Analysts raised their outlook for Mirum. HC Wainwright maintained a Buy rating and increased its price target to $195 from $140, while lifting its FY2027 EPS estimate to $1.42 from $1.28. Baird also raised its target to $130 and reiterated Outperform. Mirum Pharmaceuticals Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: A head-to-head survey compared Mirum with Sarepta Therapeutics, but the report does not represent a new operating or clinical catalyst for MIRM. Mirum Pharmaceuticals and Sarepta Therapeutics Head-To-Head Survey

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on liver and gastrointestinal disorders. The company's medicines are intended to address serious conditions for which available treatment options are limited.

Mirum's lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor approved in the United States for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.